Mach7 Technologies (M7T) has a market capitalization of approximately A$72M, trading at A$0.30 on the ASX. Market cap moves with the live share price.
Mach7 Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Mach7 Technologies runs a net profit margin of -33.9%, a gross margin of 5.2%, and an operating margin of -36.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Mach7 Technologies reported revenue of A
Mach7 Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Mach7 Technologies carries a debt-to-equity ratio of 0.04x and a current ratio of 2.15x, with a market beta of 0.97. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mach7 Technologies (M7T) the key facts are: market cap A$72M, revenue A
Get Mach7 Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.